Trending Now
Altamira Therapeutics Ltd. (NASDAQ: CYTO) Announce Results from Study Evaluating Bentrio...
Altamira Therapeutics Ltd. (NASDAQ: CYTO) has announced positive efficacy data from the study of its Bentruo nasal spray against the Delta variant of the...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Cerus Corporation (NASDAQ:CERS) Receives FDA Approval for INTERCEPT Blood System for...
Cerus Corporation (NASDAQ:CERS) has announced that the US FDA has approved the INTERCEPT Blood System for Cryoprecipitation.The system is vital in the...
MAKE IT MODERN
LATEST REVIEWS
Novavax Inc. (NASDAQ:NVAX) Amends Current Manufacturing Agreement With Serum Institute To...
Novavax Inc. (NASDAQ:NVAX) has announced that it has amended its manufacturing agreement with Serum Institute of India Private Limited. Under the amendment Serum Institute...
MAKE IT MODERN
PERFORMANCE TRAINING
NovaBay Pharmaceuticals (NYSE:NBY) Reports Revenues Of $1.9 Million In Q4 2020: Targets Beauty Market...
NovaBay Pharmaceuticals (NYSE:NBY) reported a growth of 10% YoY in Q4 2020 revenues to $1.9 million. Its full-year revenues are $9.9 million (up 51%...
Ocugen Inc (NASDAQ: OCGN) Announces the Recommendation By The Independent Data and Safety Monitory...
Ocugen Inc (NASDAQ: OCGN) recently announced that the Independent Data and safety monitory Board evaluated the safety data recorded during the clinical trial of...
The FDA Accepts an NDA for umbralisib From TG Therapeutics Inc common stock (NASDAQ:TGTX)...
From the beginning, TG Therapeutics Inc common stock (NASDAQ:TGTX) has always had big dreams of challenging the status quo of drug development. Over the...
Ocular Therapeutix™ (NASDAQ:OCUL) Report Net Revenue Of $5.9 Million In Q3 2020 Driven By...
Ocular Therapeutix™ (NASDAQ:OCUL) has announced its Q3 2020 financial results in which DEXTENZA® net product revenue was up 280% QoQ and also provided its...
British Journal of Haematology Publishes Post-Hoc Analysis of Tavalisse for Adults with Chronic Immune...
The COVID-19 global pandemic is biting harder by the day, and it seems like it is here to stay. Hence there remains a serious...
MAKE IT MODERN
